AstraZeneca's Andexxa will no longer be sold or manufactured in the US following FDA concerns around the drug's association ...

MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem ...

Novartis has reached an agreement with the US government with the aim of reducing the price of innovative medicines and ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.

Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.

Large deals in H2 2025 included Novartis’ $12 billion acquisition of Avidity Biosciences and Genmab’s buyout of Merus, ...

Poised to become law, the BIOSECURE Act will have ramifications for certain US-China pharmaceutical relationships.

Depo Provera’s label change comes amidst a flurry of over 2,000 lawsuits from women alleging that the contraceptive caused ...

INCOG BioPharma Services has announced an injectable drug manufacturing expansion at its Fishers facility in Indiana, US.